Hillhouse Capital and Chinese healthcare-focused investment firm Decheng Capital have led a US$60 million series B found in San Diego-based DNA sequencing platform developer Omniome, Inc.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 3 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription for $359
Enjoy comprehensive and exclusive data you can't find elsewhere!Subscribe for $359
Already have an account or paid subscription?